Efficacy of cefoperazone/sulbactam for ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and the factors associated with poor outcomes.
Rou-Zhen ChenPo-Liang LuTsung-Ying YangShang-Yi LinHung-Jen TangFeng-Yee ChangYa-Sung YangTsung-Ta ChiangFu-Der WangTing-Shu WuShian-Sen ShieMao-Wang HoJien-Wei LiuZhi-Yuan ShiChia-Huei ChouYin-Ching ChuangPublished in: The Journal of antimicrobial chemotherapy (2024)
CPZ/SUL demonstrated a clinical success rate of 82.7% (91/110) in treating ESBL-producing Enterobacterales bacteraemia. Treatment success was evident when the CPZ and SUL MIC was ≤32/32 mg/L. Comorbidities (CCI ≥6) were associated with lower clinical success, while disease severity (Sequential Organ Failure Assessment score ≥6) correlated with higher mortality.